Mitral regurgitation (MR) is the most common type of valvular heart disease, affecting over 2% of the world population, and the gold-standard treatment is surgical mitral valve repair/replacement. Compared to open-heart surgeries, minimally invasive surgeries (MIS) using transcatheter approaches have become popular because of their notable benefits such as less postoperative pain, shorter hospital stay, and faster recovery time. However, commercially available catheters are manually actuated, causing over-exposure of clinical staff to radiation and increased risk of human error during medical interventions. To tackle this problem, in this letter, we propose a telerobotic transcatheter delivery system, which consists of a robotic catheter (5.7 mm OD), a reinforced guide tube (1.11m length), and an actuation system. We present the robotic system design, fabrication of key components, and static model of reinforced quadlumen tube. The robot interface design enables the user to intuitively control the robot. We demonstrate the effectiveness of the telerobotic transcatheter delivery system and reinforced quadlumen tube in a realistic human cardiovascular phantom for preclinical evaluation.
Keyphrases
- minimally invasive
- endothelial cells
- mitral valve
- postoperative pain
- healthcare
- induced pluripotent stem cells
- robot assisted
- tissue engineering
- randomized controlled trial
- systematic review
- heart failure
- pluripotent stem cells
- physical activity
- magnetic resonance
- pulmonary hypertension
- contrast enhanced
- combination therapy
- stem cells
- left ventricular
- radiation induced
- replacement therapy
- image quality
- low cost
- silver nanoparticles
- drug induced